Cargando…

Editorial on “Cell Therapy, Bispecific Antibodies and Other Immunotherapies against Cancer”

Detalles Bibliográficos
Autor principal:	Golubovskaya, Vita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605091/ https://www.ncbi.nlm.nih.gov/pubmed/37894420 http://dx.doi.org/10.3390/cancers15205053

Ejemplares similares

Editorial on Special Issue “Immunotherapy, Tumor Microenvironment and Survival Signaling”
por: Golubovskaya, Vita
Publicado: (2021)

Editorial On “Exosomes, Their Biogenesis and Role in Inter-Cellular Communication, Tumor Microenvironment and Cancer Immunotherapy”
por: Golubovskaya, Vita, et al.
Publicado: (2020)

Editorial: Bispecific Antibodies for T-Cell Based Immunotherapy
por: Santich, Brian H., et al.
Publicado: (2020)

Editorial: Novel immunotherapies to treat gastrointestinal solid tumor cancers
por: Sureban, Sripathi M., et al.
Publicado: (2022)

CAR-T Cell Therapy: From the Bench to the Bedside
por: Golubovskaya, Vita
Publicado: (2017)

Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth
por: Wu, Lijun, et al.
Publicado: (2022)

Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy
por: Blanco, Belén, et al.
Publicado: (2021)

Cancer Immunotherapy: Where Next?
por: Bodmer, Walter, et al.
Publicado: (2023)

Bispecific antibodies come to the aid of cancer immunotherapy
por: Amelio, Ivano, et al.
Publicado: (2021)

Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody
por: Moon, Dain, et al.
Publicado: (2022)

Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy
por: Golubovskaya, Vita, et al.
Publicado: (2016)

Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy
por: Zhou, Shu-juan, et al.
Publicado: (2017)

Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
por: You, Gihoon, et al.
Publicado: (2021)

Enhancing the antitumor potency of T cells redirected by bispecific antibodies
por: Chang, Chien-Hsing, et al.
Publicado: (2017)

Editorial: Antibodies and other biopharmaceuticals
por: Jungbauer, Alois
Publicado: (2008)

Current landscape and future directions of bispecific antibodies in cancer immunotherapy
por: Wei, Jing, et al.
Publicado: (2022)

Bispecific Antibody-Bound T Cells as a Novel Anticancer Immunotherapy
por: Cho, Jaewon, et al.
Publicado: (2022)

Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma
por: Rampotas, Alexandros, et al.
Publicado: (2021)

Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
por: Zhou, Yanchen, et al.
Publicado: (2022)

mRNA-Lipid Nanoparticle (LNP) Delivery of Humanized EpCAM-CD3 Bispecific Antibody Significantly Blocks Colorectal Cancer Tumor Growth
por: Golubovskaya, Vita, et al.
Publicado: (2023)

Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
por: Del Bano, Joanie, et al.
Publicado: (2015)

Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy
por: Yang, Yan, et al.
Publicado: (2021)

Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question
por: Ordóñez-Reyes, Camila, et al.
Publicado: (2022)

Editorial: Global Regulatory Initiatives Deliver Accelerated Approval of the First Bispecific Therapeutic Monoclonal Antibody for Advanced Non-Small Cell Lung Cancer (NSCLC)
por: Parums, Dinah V.
Publicado: (2021)

Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell–Redirected Bispecific Antibodies
por: Lussana, Federico, et al.
Publicado: (2021)

Bispecific Antibodies and Gene Therapy
por: Nettelbeck, Dirk M.
Publicado: (2011)

Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy
por: Lin, Tsung-Yi, et al.
Publicado: (2021)

LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer
por: Qiao, Guilin, et al.
Publicado: (2022)

Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy
por: Shin, Ha Gyeong, et al.
Publicado: (2022)

Bispecific Antibody Format and the Organization of Immunological Synapses in T Cell-Redirecting Strategies for Cancer Immunotherapy
por: Carrasco-Padilla, Carlos, et al.
Publicado: (2022)

Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy
por: Farhangnia, Pooya, et al.
Publicado: (2023)

Mechanism of action of a T cell-dependent bispecific antibody as a breakthrough immunotherapy against refractory colorectal cancer with an oncogenic mutation
por: Kamakura, Daisuke, et al.
Publicado: (2020)

Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells
por: Urbanska, Katarzyna, et al.
Publicado: (2014)

Cryogel-supported stem cell factory for customized sustained release of bispecific antibodies for cancer immunotherapy
por: Aliperta, Roberta, et al.
Publicado: (2017)

Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma
por: Golubovskaya, Vita, et al.
Publicado: (2021)

Bispecific antibodies: design, therapy, perspectives
por: Sedykh, Sergey E, et al.
Publicado: (2018)

Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy
por: Zhang, Tiancheng, et al.
Publicado: (2023)

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
por: Li, Tianye, et al.
Publicado: (2023)

Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies
por: Carrara, Stefania C., et al.
Publicado: (2022)

Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations
por: Shim, Hyunbo
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_oli0f206t4arjo7j73gn9q7mhq